This is part 3 of a series on Shingrix, the new vaccine for Singles. In a new practice for the FDA and CDC's ACIP, they actually recommended this new vaccine over the existing competitor, Zostavax. This was despite an absence of post-market safety experience. Why? This is a huge improvement in long-term efficacy of preventing this important and devastating public health problem which causes disability, pain, and death.
For more information, contact us at 859-721-1414 or myhealth@prevmedheartrisk.com. Also, check out the following resources: